LANVIS 40mg tablets medication leaflet

L01BB03 thioguanine • Antineoplastic and immunomodulating agents | Antimetabolites | Purine analogues

Thioguanine is an antimetabolite agent used in the treatment of acute leukemia and other hematologic cancers. It works by interfering with DNA and RNA synthesis in cancer cells, thereby inhibiting their growth and division.

The medication is taken orally, usually once daily, as directed by a doctor. The dosage is adjusted based on the patient's weight, clinical condition, and response to treatment.

Patients should be closely monitored to detect potential side effects, such as bone marrow suppression, nausea, or liver toxicity. It is important for patients to inform their doctor of any unusual symptoms.

Common side effects include nausea, vomiting, decreased blood cell counts, and elevated liver enzymes. In rare cases, severe reactions such as hepatotoxicity or serious infections may occur. Patients should be informed of these risks before starting treatment.

General data about LANVIS 40mg

Substance: thioguanine

Date of last drug list: 01-06-2025

Commercial code: W58869001

Concentration: 40mg

Pharmaceutical form: tablets

Quantity: 25

Product type: original

Price: 476.90 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: EXCELLA GMBH - GERMANIA

Holder: ASPEN PHARMA TRADING LIMITED - IRLANDA

Number: 7909/2015/01

Shelf life: 5 years

Compensation lists for LANVIS 40mg ASPEN

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

476.90 RON

476.90 RON

0.00 RON